Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.92 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 2× Halozyme Therapeutics Inc. Common Stock's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| HALO | RPRX | |
|---|---|---|
Market Cap | $12.58B | $25.27B |
Volume | 2,179,278 | 3,671,183 |
Sector | Health | Health |
52-Week High | $115.22 | $63.96 |
52-Week Low | $61.63 | $35.44 |
Typical Hold Time | 1 Days | 1 Days |
Enterprise Value | $14.49B | $32.50B |
Dividend Yield | — | 1.66% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
